Know Cancer

forgot password

A Phase 1 Dose-Escalation Study of SCH 900776 as Monotherapy and in Combination With Gemcitabine in Subjects With Advanced Solid Tumors or Lymphoma

Phase 1
18 Years
Not Enrolling
Hodgkin Disease, Lymphoma, Non-Hodgkin, Neoplasms

Thank you

Trial Information

A Phase 1 Dose-Escalation Study of SCH 900776 as Monotherapy and in Combination With Gemcitabine in Subjects With Advanced Solid Tumors or Lymphoma

Inclusion Criteria:

- Must have a diagnosis of an advanced solid tumor malignancy or lymphoma
(non-Hodgkin's or Hodgkin's lymphoma).

- Must have histological or cytological evidence of malignancy.

- Must have an advanced malignancy, metastatic or unresectable. For Part A of the
study, the metastatic or unresectable malignancy should have recurred or progressed
following standard therapy or failed standard therapy; or for which no standard
therapy currently exists, or for which they are not candidates for standard therapy.
For Parts B and C of the study, participants with advanced tumors for which
gemcitabine is considered standard therapy (eg, pancreatic cancer), may be enrolled
without having received prior gemcitabine. Standard therapy is defined as therapy
that is approved in a particular line of therapy or considered as standard of care
based on published peer reviewed data in a specific line of therapy.

- Gemcitabine-naïve participants with tumors known to be responsive to gemcitabine or
participants previously treated with gemcitabine who did not progress while on
treatment or who are currently still responding to treatment should only be enrolled
in cohorts for which gemcitabine doses are >=1000 mg/m². Participants previously
treated with gemcitabine, whose disease has progressed wile on treatment, can be
enrolled to any part.

- Must be ambulatory with an Eastern Cooperative Oncology Group (ECOG) performance
status of 0 or 1.

- Must be 18 years or older, of either sex, and of any race.

- Participants (and/or parent/guardian for participants who otherwise are unable to
provide independent consent) must be willing to give written informed consent and
able to adhere to dose and visit schedules.

- Female participants of childbearing potential must have a negative pregnancy test
within 7 days of first dose of protocol therapy.

- Female participants of childbearing potential and male participants whose sexual
partners are of childbearing potential must agree to abstain from sexual intercourse
or to use an acceptable method of contraception during the study and for 90 days
following the last dose of protocol therapy. Acceptable methods of contraception
include condoms (male or female) with or without spermicidal agent, diaphragm or
cervical cap with spermicide, medically prescribed intrauterine device (IUD), oral or
injectable hormonal contraceptive, and surgical sterilization (eg, hysterectomy or
tubal ligation).

- Must have adequate bone marrow reserve as evidenced by a white blood cell (WBC) count
>=3,000/ μL, absolute neutrophil count (ANC) >=1,500/μL AND platelet count

- Must have adequate renal function as evidenced by a serum creatinine level <=1.5 x
upper limit of normal (ULN) or a calculated creatinine clearance >60 mL/min.

- Participants, except those with known Gilbert's Syndrome, must have adequate hepatic
function as evidenced by a serum bilirubin level <=1.5 x the ULN AND serum levels of
aspartate and alanine aminotransferase (AST/ALT) levels <=3 x the ULN for the
reference lab (participants with known hepatic metastases must have serum AST/ALT
levels <=5 x the ULN for the reference lab).

- Must be recovered from the effects of any prior surgery, radiotherapy or systemic
antineoplastic therapy.

Exclusion Criteria:

- Has a known hypersensitivity to SCH 900776 or gemcitabine or to any of their
excipients or has received therapy with another CHK1 inhibitor.

- Has received any prohibited medication more recently than the indicated washout
period prior to first dose of protocol therapy or must continue to receive prohibited
medications. Prohibited medications: cytochrome P450 1A2 inhibitors, any
chemotherapy, or investigational drugs.

- Has significant underlying cardiac conduction system abnormalities such as
bifascicular or greater block (eg, right bundle branch block with left anterior
hemiblock or first degree atrioventricular block), fixed-rate pacemaker, or chronic
atrial fibrillation with variable ventricular rate.

- Has persistent, unresolved Common Terminology Criteria for Adverse Events (CTCAE) v
3.0 >=Grade 2 drug-related toxicity (except alopecia, erectile impotence, hot
flashes, and decreased libido) associated with previous treatment.

- Has known human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or a known
history of liver cirrhosis or active alcohol abuse.

- Is New York Heart Association (NYHA) Class III.

- Has any other medical or psychiatric condition that, in the opinion of the
investigator, might interfere with the subject's participation in the trial or
interfere with the interpretation of trial results.

- Has undergone major surgery within 3 weeks prior to first study drug administration
after enrollment.

- Has central nervous system (CNS) or leptomeningeal metastases.

- Has received radiation therapy within 3 weeks prior to first study drug
administration after enrollment or radiation therapy to >25% of bone marrow.

- Has received more than three prior chemotherapy regimens (may have received prior
gemcitabine). A participant may not have experienced any CTCAE v 3.0 >Grade 1
myelotoxicity (neutropenia and/or thrombocytopenia) with any prior regimen, including
gemcitabine. Participants with more than three prior chemotherapy regimens, one or
more of which were targeted, nonmyelosuppressive agents, may be considered on a
case-by-case basis after discussion with the sponsor.

- Has undergone previous allogeneic or autologous stem cell transplant.

- Has had any of the following within 6 months prior to first study drug administration
after enrollment: myocardial infarction, severe/unstable angina pectoris,
coronary/peripheral artery bypass graft, symptomatic congestive heart failure,
cerebrovascular accident or transient ischemic attack, or seizure disorder.

- Has a known bleeding diathesis, eg, hemophilia.

- Has a baseline QTc interval >450 msec (ie, CTCAE v 3.0 Grade ≥2) at screening (within
21 days prior to 1st dose of SCH 900776, mean of triplicate readings within
approximately 5 minutes).

- History of risk factors for Torsades de Pointes, including clinical history of heart
failure, hypo- or hyperkalemia or hypomagnesemia (supplementation or other
appropriate interventions to bring levels within normal institutional limits prior to
administration of SCH 900776 is acceptable), or family history of Long QT Syndrome.

- Currently a smoker and/or is likely to smoke during the study.

- Female participant who is breast-feeding, pregnant, or intends to become pregnant.

- Participating in any other interventional clinical study. (Subject participating in
another noninterventional study may be considered after discussion with the sponsor.)

- Part of the staff personnel directly related to this study.

- Family member of one of the investigational staff.

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Dose-limiting toxicities and biologic activity used to determine the recommended Phase 2 combination doses of SCH 900776 and gemcitabine

Outcome Time Frame:

All study visits

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

October 2008

Completion Date:

May 2011

Related Keywords:

  • Hodgkin Disease
  • Lymphoma, Non-Hodgkin
  • Neoplasms
  • Neoplasms
  • Hodgkin Disease
  • Lymphoma
  • Lymphoma, Non-Hodgkin